Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Bristol-Myers Squibb ( (BMY) ) just unveiled an announcement.
On July 25, 2025, Bristol Myers Squibb announced the departure of Dr. Samit Hirawat, the Chief Medical Officer and Head of Development, effective November 1, 2025. Dr. Hirawat will transition to an advisory role starting August 1, 2025, and will receive severance benefits and prorated incentives. Concurrently, Dr. Cristian Massacesi will join the company as the new Executive Vice President, Chief Medical Officer, and Head of Development, effective August 1, 2025. Dr. Massacesi brings extensive experience from his previous roles at AstraZeneca and Alexion, and his appointment is expected to bolster Bristol Myers Squibb’s efforts in advancing its product pipeline and achieving regulatory approvals.
The most recent analyst rating on (BMY) stock is a Buy with a $64.00 price target. To see the full list of analyst forecasts on Bristol-Myers Squibb stock, see the BMY Stock Forecast page.
Spark’s Take on BMY Stock
According to Spark, TipRanks’ AI Analyst, BMY is a Outperform.
Bristol-Myers Squibb’s overall stock score reflects a balanced view of its strengths and risks. The company’s robust cash flow and increased financial guidance from its earnings call are significant positives. However, variability in net income and external regulatory challenges temper the outlook. The stock offers an attractive dividend yield, enhancing its appeal despite technical indicators suggesting potential resistance.
To see Spark’s full report on BMY stock, click here.
More about Bristol-Myers Squibb
Bristol Myers Squibb is a global biopharmaceutical company focused on discovering, developing, and delivering innovative medicines that help patients prevail over serious diseases. The company is committed to advancing science across various therapeutic areas, including oncology, hematology, immunology, cardiovascular, and neuroscience.
Average Trading Volume: 14,294,098
Technical Sentiment Signal: Sell
Current Market Cap: $99.6B
See more insights into BMY stock on TipRanks’ Stock Analysis page.